Validation and performance assessment of a commercial anti-peroxidasin antibody

Peroxidasin (PXDN) is a multi-domain heme peroxidase that catalyzes sulfilimine cross-links in type IV collagen, a reaction essential for basement membrane stability. In addition to its structural role, PXDN has been implicated in oxidative stress regulation, fibrosis, and tumorigenesis. Antibody-based detection is critical for defining PXDN expression and localization, yet few commercial reagents have been rigorously validated, limiting reproducibility. Here, we assessed the specificity and performance of a commercially available anti-PXDN antibody (Abbexa, abx101906) in immunohistochemistry and immunocytochemistry applications. Validation was performed in formalin-fixed, paraffin-embedded human kidney tissue and in a primary kidney fibroblast line under PXDN silencing and overexpression conditions. The antibody yielded reproducible labeling patterns and demonstrated specificity across cellular contexts. These findings establish abx101906 as a reliable tool for immunofluorescence-based detection of PXDN. This validation provides a foundation for future studies of PXDN biology in kidney development, disease, and potential therapeutic targeting.